Evidence map›Paper›PMID 36900372›Full record

ArticleCancers2023

Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group.

Christoph Thomssen, Martina Vetter, Eva J Kantelhardt, Christoph Meisner, Marcus Schmidt, Pierre M Martin, Florian Clatot, Doris Augustin, Volker Hanf, Daniela Paepke and 10 more

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Christoph ThomssenDepartment of Gynaecology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany.
Martina VetterDepartment of Gynaecology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany.
Eva J KantelhardtDepartment of Gynaecology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany.ORCID 0000-0001-7935-719X
Christoph MeisnerInstitute for Clinical Epidemiology and Applied Biometry, D-72076 Tuebingen, Germany.ORCID 0000-0002-4802-3100
Marcus SchmidtDepartment of Gynaecology, Johannes-Gutenberg University, D-55131 Mainz, Germany.ORCID 0000-0003-1365-2414
Pierre M MartinDepartment of Medical Oncology, Medical Faculty, F-13344 Marseille, France.
Florian ClatotDepartment of Medical Oncology, Henri Becquerel Center, F-76038 Rouen, France.
Doris AugustinDepartment of Gynaecology, Klinikum Deggendorf, D-94469 Deggendorf, Germany.
Volker HanfDepartment of Gynaecology, Nathanstift, Hospital Fürth, D-90766 Fürth, Germany.
Daniela PaepkeDepartment of Gynaecology, Technische Universitaet Muenchen, D-81675 Munich, Germany.ORCID 0009-0002-2499-7194
Wolfgang MeinerzDepartment of Gynaecology, St. Vincenz Hospital, D-33098 Paderborn, Germany.
Gerald HoffmannDepartment of Gynecology, St. Josephs-Hospital, D-65189 Wiesbaden, Germany.
Wolfgang WiestDepartment of Gynaecology, Katholisches Klinikum, D-55131 Mainz, Germany.
Fred C G J SweepDepartment of Laboratory Medicine, Radboud University Medical Center, NL-6500 HB Nijmegen, The Netherlands.ORCID 0000-0003-1103-3070
Manfred SchmittDepartment of Gynaecology, Technische Universitaet Muenchen, D-81675 Munich, Germany.
Fritz JänickeDepartment of Gynaecology, University Medical Center Hamburg-Eppendorf, D-20251 Hamburg, Germany.
Sibylle LoiblGerman Breast Group Forschungs-GmbH, D-63263 Neu-Isenburg, Germany.
Gunter von MinckwitzGerman Breast Group Forschungs-GmbH, D-63263 Neu-Isenburg, Germany.
Nadia HarbeckBreast Center, Ludwig-Maximilian University Hospital, D-81377 Munich, Germany.ORCID 0000-0002-9744-7372
NNBC 3-Europe Study Group

Funding

AGO-B Breast Study Group #AGOB001FP4 BIOMED 2 #BMH4 98-3418Martin Luther University Halle-Wittenberg NBL Program #FKZ 15/29 and 17/37Sanofi-Aventis Germany #NNBC-3 31/10/2002
6 · The paper itself

Abstract

backgroundIn node-negative breast cancer (NNBC), a high risk of recurrence is determined by clinico-pathological or tumor-biological assessment. Taxanes may improve adjuvant chemotherapy.

methodsNNBC 3-Europe, the first randomized phase-3 trial in node-negative breast cancer (BC) with tumor-biological risk assessment, recruited 4146 node-negative breast cancer patients from 2002 to 2009 in 153 centers. Risk assessment was performed by clinico-pathological factors (43%) or biomarkers (uPA/PAI-1, urokinase-type plasminogen activator/its inhibitor PAI-1). High-risk patients received six courses 5-fluorouracil (500 mg/m

resultsIn the intent-to-treat population, 1286 patients had received FEC-Doc, and 1255 received FEC. Median follow-up was 45 months. Tumor characteristics were equally distributed; 90.6% of tested tumors had high uPA/PAI-1-concentrations. Planned courses were given in 84.4% (FEC-Doc) and 91.5% (FEC). Five-year-DFS was 93.2% (95% C.I. 91.1-94.8) with FEC-Doc and 93.7% (91.7-95.3) with FEC. Five-year-overall survival was 97.0% (95.4-98.0) for FEC-Doc and 96.6% % (94.9-97.8) for FEC.

conclusionsWith adequate adjuvant chemotherapy, even high-risk node-negative breast cancer patients have an excellent prognosis. Docetaxel did not further reduce the rate of early recurrences and led to significantly more treatment discontinuations.

Indexed as

adjuvant chemotherapydocetaxelnode-negative breast canceruPA/PAI-1

Identifiers

PMID36900372
PMCPMC10001055

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read58
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.